| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | MICROVASCULAR THERAPEUTICS INC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43CA272149 | Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors. | 000 | 1 | NIH | 11/25/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = -$6 ) |
| | 2024 | 2023 | MICROVASCULAR THERAPEUTICS INC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | SB1HL137447 | MVT-100 Manufacturing and Commercialization. | 000 | 4 | NIH | 4/23/2024 | $0 |
| | 2024 | 2022 | MICROVASCULAR THERAPEUTICS INC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R33HL156350 | Ultrasound-mediated thrombolysis for MVO and PAO treatment. | 000 | 2 | NIH | 1/19/2024 | $0 |
| | 2024 | 2020 | MICROVASCULAR THERAPEUTICS INC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43AG067894 | Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques. | 000 | 1 | NIH | 12/22/2023 | -$6 |
| | 2024 | 2019 | MICROVASCULAR THERAPEUTICS INC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 2 | NIH | 12/19/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $206,081 ) |
| | 2023 | 2023 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | SB1HL137447 | MVT-100 Manufacturing and Commercialization. | 000 | 4 | NIH | 4/7/2023 | $206,081 |
| | 2023 | 2022 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43CA272149 | Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors. | 000 | 1 | NIH | 12/9/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,039,965 ) |
| | 2022 | 2022 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R33HL156350 | Ultrasound-mediated thrombolysis for MVO and PAO treatment. | 000 | 2 | NIH | 6/6/2022 | $350,219 |
| | 2022 | 2022 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | SB1HL137447 | MVT-100 Manufacturing and Commercialization. | 000 | 3 | NIH | 3/23/2022 | $292,149 |
| | 2022 | 2022 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43CA272149 | Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors. | 000 | 1 | NIH | 9/19/2022 | $397,597 |
| | 2022 | 2020 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43HL152819 | Ultrasound-Stimulated Phase-Change Contrast Agents for Sonothrombolysis. | 000 | 1 | NIH | 7/1/2022 | $0 |
| | 2022 | 2020 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43AG067894 | Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques. | 000 | 1 | NIH | 4/8/2022 | $0 |
| | 2022 | 2019 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 002 | 2 | NIH | 8/10/2022 | $0 |
| | 2022 | 2019 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 2 | NIH | 11/9/2021 | $0 |
| | 2022 | 2019 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 001 | 2 | NIH | 3/24/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $559,347 ) |
| | 2021 | 2021 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R33HL156350 | Ultrasound-mediated thrombolysis for MVO and PAO treatment. | 000 | 1 | NIH | 7/8/2021 | $575,012 |
| | 2021 | 2020 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43AG067894 | Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques. | 000 | 1 | NIH | 2/12/2021 | -$15,665 |
|
| Issue Date FY: 2020 ( Subtotal = $789,361 ) |
| | 2020 | 2020 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43AG067894 | Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques. | 000 | 1 | NIH | 7/21/2020 | $411,171 |
| | 2020 | 2020 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R43HL152819 | Ultrasound-Stimulated Phase-Change Contrast Agents for Sonothrombolysis. | 000 | 1 | NIH | 7/17/2020 | $378,190 |
| | 2020 | 2019 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 2 | NIH | 4/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $384,549 ) |
| | 2019 | 2019 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 001 | 2 | NIH | 9/6/2019 | $384,549 |
| | 2019 | 2017 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 1 | NIH | 2/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2017 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 1 | NIH | 7/25/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,229,385 ) |
| | 2017 | 2017 | MICROVASCULAR THERAPEUTICS LLC | 1635 E 18TH ST | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL137447 | Development of New Improved Perflutren Ultrasound Contrast Agent | 000 | 1 | NIH | 8/17/2017 | $1,229,385 |
|
| Issue Date FY: 2010 ( Subtotal = -$178,273 ) |
| | 2010 | 2007 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719-6803 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 000 | 4 | NIH | 11/17/2009 | -$178,273 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2007 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 000 | 4 | NIH | 3/20/2009 | $0 |
|
| Issue Date FY: 2007 ( Subtotal = $746,008 ) |
| | 2007 | 2007 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 000 | 4 | NIH | 7/17/2007 | $303,669 |
| | 2007 | 2007 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R41NS057860 | TARGETED BLOOD BRAIN BARRIER PERMEABILITY CHANGES WITH ULTRASOUND & MICROBUBBLES | 000 | 1 | NIH | 8/20/2007 | $442,339 |
|
| Issue Date FY: 2006 ( Subtotal = $402,876 ) |
| | 2006 | 2006 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 000 | 3 | NIH | 6/28/2006 | $402,876 |
|
| Issue Date FY: 2005 ( Subtotal = $381,903 ) |
| | 2005 | 2005 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R44HL071433 | SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES | 000 | 2 | NIH | 7/5/2005 | $381,903 |
|
| Issue Date FY: 2002 ( Subtotal = $100,000 ) |
| | 2002 | 2002 | IMARX THERAPEUTICS, INC | 1635 EAST 18TH STREET | TUCSON | AZ | 85719 | PIMA | USA | R43CA091503 | NOVEL NANOPARTICLE DELIVERY SYSTEM FOR ANTINEOPLASTICS | 000 | 1 | NIH | 5/22/2002 | $100,000 |
|
|
